Spots Global Cancer Trial Database for A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer
Official Title: A Phase Ib, Single Arm, Open-label Study of TQB2450 Combined With Anlotinib in Subjects With Relapsed / Refractory Gynecological Cancer
Study ID: NCT04236362
Conditions
Study Description
Brief Summary: This is a single-arm, open-label, phase Ib clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib in subjects with gynecological cancer, including 34 ovarian cancer，34 endometrial cancer，22 cervical cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The General Hospital of the People's Liberation Army, Beijing, Beijing, China
Cancer Hospital of Chongqing University, Chongqing, Chongqing, China
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
